Yalda Olcott, PharmD, Joins Noom as Head of Healthcare and Pharmacy Operations
October 01, 2024 08:02 ET
|
Noom Inc
Noom announces the appointment of Yalda Olcott, PharmD, as Head of Healthcare and Pharmacy Operations.
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions
October 01, 2024 07:00 ET
|
Kailera Therapeutics, Inc.
Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.
LeaderMed Group and Combiphar Form Joint Venture on LM-008, a Novel GLP-1 Dual Agonist, Targeting Indonesia's High Diabetes and/or Obesity Prevalence
September 30, 2024 22:00 ET
|
LeaderMed Group; Combiphar
LeaderMed and Combiphar form a joint venture to tackle Indonesia’s diabetes and obesity crisis with LM-008 and UltraSculpt, launching a Phase 3 trial.
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
September 25, 2024 08:30 ET
|
Entera Bio Ltd.; OPKO Health, Inc.
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO)...
Noom Calls for Affordable Choices and Fair Pricing of Weight-Loss Medications Ahead of Tuesday’s Senate Testimony
September 24, 2024 07:02 ET
|
Noom Inc
Noom issued a call for public support of a new petition demanding affordable choices and fair pricing for GLP-1 weight-loss medications.
Noom Appoints Rachel Mahoney as Chief Brand Officer
September 17, 2024 08:02 ET
|
Noom Inc
Noom is pleased to announce the appointment of Rachel Mahoney as Chief Brand Officer.
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
September 12, 2024 08:03 ET
|
Noom Inc
Noom will offer compounded GLP-1 injections paired with Noom’s powerful GLP-1 companion program, providing a sustainable pathway off the medications.
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
August 28, 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy®...
Sesame, America’s Low-Cost Leader in Healthcare, Makes Compounded Semaglutide Available to Eligible Patients “At Cost,” with no Retail Price Markup
August 21, 2024 09:00 ET
|
Sesame
NEW YORK CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Sesame, the company that offers Americans quality, convenient health care at half the typical price, today announced the launch of “Success by...
Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly
August 08, 2024 05:00 ET
|
Defiance ETFs
Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly